U.S., June 16 -- ClinicalTrials.gov registry received information related to the study (NCT07647328) titled 'A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer' on May 12.
Brief Summary: The purpose of this study is to investigate the efficacy, safety, and tolerability of camizestrant in combination with ribociclib in patients with ER+ HER2- BC who have not received any other systemic treatment for advanced disease. Participants will be treated within the trial until they discontinue the study treatment for any reason.
Study Start Date: May 26
Study Type: INTERVENTIONAL
Condition:
ER-Positive HER2-Negative Breast Cancer
Intervention:
DRUG: Camizestrant
Patients will recei...